Clear Harbor Asset Management LLC Lowers Stake in IQVIA Holdings Inc. $IQV

Clear Harbor Asset Management LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 17.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,158 shares of the medical research company’s stock after selling 2,419 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in IQVIA were worth $2,119,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. HB Wealth Management LLC grew its stake in IQVIA by 32.4% in the third quarter. HB Wealth Management LLC now owns 3,501 shares of the medical research company’s stock valued at $665,000 after purchasing an additional 857 shares during the last quarter. Moran Wealth Management LLC purchased a new stake in shares of IQVIA during the third quarter valued at about $7,939,000. Park Avenue Securities LLC boosted its holdings in shares of IQVIA by 8.5% in the 3rd quarter. Park Avenue Securities LLC now owns 6,469 shares of the medical research company’s stock valued at $1,229,000 after buying an additional 506 shares in the last quarter. KLP Kapitalforvaltning AS grew its position in shares of IQVIA by 0.5% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 64,975 shares of the medical research company’s stock worth $12,341,000 after buying an additional 300 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of IQVIA by 15.1% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 1,266 shares of the medical research company’s stock worth $240,000 after acquiring an additional 166 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on IQV. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. BMO Capital Markets initiated coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Citigroup boosted their price target on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. Finally, UBS Group increased their price objective on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $246.63.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.60% of the company’s stock.

IQVIA Trading Down 0.5%

Shares of NYSE:IQV opened at $243.18 on Friday. The business has a 50-day moving average price of $223.85 and a 200-day moving average price of $199.58. The stock has a market cap of $41.41 billion, a price-to-earnings ratio of 33.36, a PEG ratio of 2.49 and a beta of 1.36. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $246.71. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.